Calbindin-immunoreactive cholinergic neurones in the nucleus basalis of Meynert in Alzheimer-type dementia.
An antibody to the calcium binding protein, calbindin D28K (CaBP), was used to study the number and size of CaBP-immunoreactive neurones in the nucleus basalis of Meynert (nbM) of postmortem human brains from neurologically normal controls and from patients with neuropathologically diagnosed Alzheimer-type dementia (ATD). In controls, almost all the large neurones and their processes in the nbM were CaBP immunoreactive. Compared to neurologically normal controls the number of CaBP-immunoreactive neurones in the nbM in patients dying with ATD was significantly reduced and there was a clear loss of the majority of CaBP immunoreactive neurones. The few remaining nbM CaBP immunoreactive neurones in the ATD cases were smaller than those in the neurologically normal controls. Double-staining experiments revealed that many of the nbM CaBP-immunoreactive neurones contained choline acetyltransferase immunoreactivity, so that CaBP is an alternative marker for the nbM cholinergic neurones in the human fore-brain. These findings suggest that a disturbance in calcium homeostasis may be a possible factor contributing to the loss of these cholinergic/CaBP-containing neurones.
Ichimiya
Y
Y
MRC Group, AFRC Institute of Animal Physiology and Genetics Research, Babraham, Cambridge, U.K.
Emson
P C
PC
Mountjoy
C Q
CQ
Lawson
D E
DE
Iizuka
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D001479:Basal Ganglia / Q000378:metabolism*; D064092:Calbindin 1; D064026:Calbindins; D002799:Cholinergic Fibers / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D064030:S100 Calcium Binding Protein G / Q000378:metabolism*; D013377:Substantia Innominata / Q000378:metabolism* / Q000473:pathology
C576498:CALB1 protein, human; D064092:Calbindin 1; D064026:Calbindins; D064030:S100 Calcium Binding Protein G